Peer-reviewed veterinary case report
Survival after surgery and DNA vaccine for dogs with oral melanoma
By Treggiari, Elisabetta et al.·Published in The Journal of veterinary medical science·2016·VRCC Veterinary Referrals, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma.
- Species:
- dog
Plain-English summary
A group of 32 dogs with oral malignant melanoma (a type of mouth cancer) underwent surgery and received a special DNA vaccine to help fight the disease. The average survival time after treatment was about 335 days, with some dogs living longer than a year. The study found that factors like how much cancer was removed during surgery and how quickly the vaccine was given didn't significantly change survival rates. While the results are promising, more research is needed to see if this combination of treatments can help dogs live even longer after surgery.
People also search for: dog oral melanoma treatment · canine cancer vaccine · how long do dogs live with mouth cancer
Abstract
A xenogeneic DNA vaccination has been licensed for use in dogs with locally controlled stage II and III oral malignant melanoma (OMM). At present, there are limited outcome data for dogs with OMM treated with surgery and immunotherapy. The aim of this study is to retrospectively review the outcome and survival of 32 dogs affected by OMM that were treated with a combination of surgery and the xenogeneic DNA vaccination (with the addition of radiotherapy in some cases) and to determine the influence of surgical margins and delay in receiving vaccination. The overall median survival time (MST) was 335 days (95% CI: 301-540 days), and the overall median progression-free survival (PFS) was 160 days (mean 182 days, 95% CI: 132-232 days). Stage, completeness of surgical margins and delay in administration of the vaccine did not appear to statistically influence survival or PFS, although these results may reflect the low statistical power of the study due to small numbers. Further studies are required to assess whether the addition of any adjuvant treatment to surgery, including immunotherapy, is able to significantly prolong survival in cases of canine oral melanoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/26781703/